Published in J Transl Med on November 13, 2011
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. Eur J Cancer (2015) 1.53
Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer (2014) 1.35
Vaccines for pancreatic cancer. Cancer J (2012) 0.90
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med (2012) 0.87
Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. Cancer Biol Ther (2015) 0.82
Recent new drug approvals, part 2: drugs undergoing active clinical studies in children. J Pediatr Pharmacol Ther (2013) 0.82
Comparative antitumor effect of preventive versus therapeutic vaccines employing B16 melanoma cells genetically modified to express GM-CSF and B7.2 in a murine model. Toxins (Basel) (2012) 0.82
Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities. Front Immunol (2012) 0.80
New treatment approaches in melanoma: current research and clinical prospects. Ther Adv Med Oncol (2013) 0.78
Blocking monoclonal antibodies of TIM proteins as orchestrators of anti-tumor immune response. MAbs (2014) 0.76
Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells. Onco Targets Ther (2013) 0.76
PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab. Am J Cancer Res (2016) 0.75
IL-10: Expanding the Immune Oncology Horizon. Receptors Clin Investig (2015) 0.75
Melanoma: the role of surgery in the era of new therapies. J Transl Med (2014) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol (2010) 5.91
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature (1999) 5.76
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A (2008) 3.04
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73
Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol (2009) 2.53
Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res (2010) 2.20
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs (2010) 2.09
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol (2010) 1.98
The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res (2011) 1.56
Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res (2010) 1.42
Melanoma: a model for testing new agents in combination therapies. J Transl Med (2010) 1.39
Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother (2009) 1.36
Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma. J Oncol Pharm Pract (2011) 0.96
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature (2010) 10.09
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature (2012) 8.13
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med (2010) 5.57
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (2013) 5.09
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun (2012) 4.94
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 4.80
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
Tumor immunotherapy directed at PD-1. N Engl J Med (2012) 4.43
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15
Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51
Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol (2005) 3.23
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol (2009) 3.02
Tumour immunity: effector response to tumour and role of the microenvironment. Lancet (2008) 2.94
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity (2013) 2.86
The immune score as a new possible approach for the classification of cancer. J Transl Med (2012) 2.79
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov (2014) 2.74
Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res (2007) 2.69
MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med (2010) 2.57
HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med (2009) 2.56
A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells. Nat Med (2011) 2.54
Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol (2009) 2.53
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov (2012) 2.48
MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res (2010) 2.48
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45
Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res (2011) 2.42
BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature (2013) 2.36
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res (2012) 2.31
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest (2013) 2.30
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov (2012) 2.27
Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol (2005) 2.24
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol (2012) 2.21
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res (2012) 2.14
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol (2013) 2.13
Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol (2007) 2.10
Lost in Translation: Obstacles to Translational Medicine. J Transl Med (2004) 2.03
The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res (2010) 2.02
The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00
A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat (2011) 1.99
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther (2002) 1.96
Gene expression profiling of cutaneous wound healing. J Transl Med (2007) 1.91
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest (2011) 1.90
Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One (2011) 1.89
Quantitative real-time PCR: a powerful ally in cancer research. Trends Mol Med (2003) 1.88
MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells. J Transl Med (2009) 1.85
What's next in translational medicine? Clin Sci (Lond) (2007) 1.85
Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res (2003) 1.83
In support of descriptive studies; relevance to translational research. J Transl Med (2007) 1.82
Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res (2009) 1.81
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov (2013) 1.75
Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res (2005) 1.74
Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol (2002) 1.74
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
The dual role of IL-10. Trends Immunol (2003) 1.72
Clonal persistence and evolution during a decade of recurrent melanoma. J Invest Dermatol (2006) 1.69
Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. Cancer Discov (2013) 1.68
CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res (2014) 1.66
The immunologic constant of rejection. Trends Immunol (2008) 1.62
Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc Natl Acad Sci U S A (2011) 1.61
T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res (2008) 1.61
Investigation of residual hepatitis C virus in presumed recovered subjects. Hepatology (2012) 1.61
Obstacles and opportunities in translational research. Nat Med (2005) 1.59
Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force. J Transl Med (2010) 1.57
Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med (2008) 1.57
Common cancer biomarkers. Cancer Res (2006) 1.56
Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst (2002) 1.56
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med (2008) 1.56
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res (2014) 1.55
What have we learned from cancer immunotherapy in the last 3 years? J Transl Med (2014) 1.52
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J (2014) 1.51
Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nat Immunol (2011) 1.51
An immunologic portrait of cancer. J Transl Med (2011) 1.50
Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: potential for diagnostic applications. Am J Clin Pathol (2002) 1.48
Research translation: a new frontier for clinical laboratories. Clin Chem Lab Med (2006) 1.48
A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res (2006) 1.48
Selection and validation of endogenous reference genes using a high throughput approach. BMC Genomics (2004) 1.45
A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther (2011) 1.45
Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. J Immunol (2004) 1.44